Pharmacokinetics of voclosporin in renal impairment and hepatic impairment

2013 ◽  
Vol 53 (12) ◽  
pp. 1303-1312 ◽  
Author(s):  
S.Y. Ling ◽  
R.B. Huizinga ◽  
P.R. Mayo ◽  
D.G. Freitag ◽  
L.J. Aspeslet ◽  
...  
Keyword(s):  
Renal Impairment ◽  
Hepatic Impairment

scholarly journals A case of refractory ascites

2015 ◽  
Vol 4 (3S) ◽  
pp. 31-35
Author(s):  
Loris Varvello ◽  
Celeste Arnò ◽  
Angelo Bosio ◽  
Flavio Cerrato ◽  
Gabriele Monaco ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Renal Impairment ◽  
Orthotopic Liver Transplantation ◽  
Hepatic Impairment ◽  
Alcoholic Cirrhosis ◽  
Therapeutic Options ◽  
Refractory Ascites ◽  
High Dose

We describe a case of patient with alcoholic cirrhosis and severe functional hepatic impairment (Child C), developing in the last months renal impairment too and ingravescent, refractory ascites, despite high-dose diuretics. The patient was treated with intravenous albumin and, at last, weekly paracentesis. In this report we evaluate alternative therapeutic options (Transjugular Inrtahepatic Protosystemic Shunt, Orthotopic Liver Transplantation) when frequent paracentesis are needed.

The Pharmacokinetics of Toborinone in Subjects with Congestive Heart Failure and Concomitant Renal Impairment and/or Concomitant Hepatic Impairment

2002 ◽  
Vol 42 (12) ◽  
pp. 1318-1325 ◽  
Author(s):  
Brinda Tammara ◽  
John M. Trang ◽  
Mami Kitani ◽  
Gohachiro Miyamoto ◽  
Steven L. Bramer
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Renal Impairment ◽  
Hepatic Impairment

scholarly journals Acute Renal Impairment in Patients Due to Paracetamol Overdose in the Absence of Hepatic Impairment

Cureus ◽  
2021 ◽  
Author(s):  
Zahid Khan ◽  
Mohammed Abumedian ◽  
Mildred Ibekwe ◽  
Khalid Musa ◽  
Gideon Mlawa
Keyword(s):  
Renal Impairment ◽  
Hepatic Impairment ◽  
Paracetamol Overdose

scholarly journals Pharmacokinetics of Tedizolid in Subjects with Renal or Hepatic Impairment

2014 ◽  
Vol 58 (11) ◽  
pp. 6471-6476 ◽  
Author(s):  
S. Flanagan ◽  
S. L. Minassian ◽  
D. Morris ◽  
R. Ponnuraj ◽  
T. C. Marbury ◽  
...  
Keyword(s):  
Renal Impairment ◽  
Hepatic Impairment ◽  
Peak Concentration ◽  
Matched Control ◽  
Severe Renal Impairment ◽  
Control Group ◽  
Crossover Fashion ◽  
Severe Hepatic Impairment ◽  
Control Subjects ◽  
Before And After

ABSTRACTTwo open-label, single-dose, parallel-group studies were conducted to characterize the pharmacokinetics of the novel antibacterial tedizolid and the safety of tedizolid phosphate, its prodrug, in renally or hepatically impaired subjects. Tedizolid pharmacokinetics in subjects with severe renal impairment without dialysis support was compared with that of matched control subjects with normal renal function. Effects of hemodialysis on tedizolid pharmacokinetics were determined in a separate cohort of subjects undergoing long-term hemodialysis. Effects of hepatic impairment on tedizolid pharmacokinetics were determined in subjects with moderate or severe hepatic impairment and compared with those of matched control subjects with normal hepatic function. Each participant received a single oral (hepatic impairment) or intravenous (renal impairment) dose of tedizolid phosphate at 200 mg; hemodialysis subjects received two doses (separated by 7 days), before and after dialysis, in a crossover fashion. The pharmacokinetics of tedizolid was similar in subjects with severe renal impairment and controls (∼8% lower area under the concentration-time curve [AUC], with a nearly identical peak concentration) and in subjects undergoing hemodialysis before and after tedizolid phosphate administration (∼9% lower AUC, with a 15% higher peak concentration); <10% of the dose was removed during 4 h of hemodialysis. Tedizolid pharmacokinetics was only minimally altered in subjects with moderate or severe hepatic impairment; the AUC was increased approximately 22% and 34%, respectively, compared with that of subjects in the control group. Tedizolid phosphate was generally well tolerated in all participants. These results suggest that tedizolid phosphate dose adjustments are not necessary in patients with any degree of renal or hepatic impairment. (This study has been registered at ClinicalTrials.gov under registration numbers NCT01452828 [renal study] and NCT01431833 [hepatic study].)

scholarly journals Population Pharmacokinetics Study of Morinidazole in Patients with Moderate Hepatic Impairment

2018 ◽  
Author(s):  
Yue Kang ◽  
Fengyan Xu ◽  
Kun Wang ◽  
Jing Zhang ◽  
Xiaojie Wu ◽  
...  
Keyword(s):  
Renal Impairment ◽  
Renal Dysfunction ◽  
Hepatic Impairment ◽  
Compartment Model ◽  
Control Group ◽  
Population Pharmacokinetic ◽  
Moderate Hepatic Impairment ◽  
Mild Renal Impairment ◽  
Mixed Effects Modeling ◽  
Adjustment Strategy

AbstractObjectiveMorinidazole is a novel third generation 5-nitroimidazole antimicrobial drug which has demonstrated substantial antibacterial activity against clinical isolates of anaerobe. The aim of this study was to build population pharmacokinetic (PPK) model of morinidazole among patients with hepatic impairment and to provide dosage adjustment strategy for morinidazole in patients with hepatic impairment and/or renal dysfunction.MethodsThe nonlinear mixed effects modeling tool NONMEM (version7.3, ICON Development Solutions) was used to develop the PPK model of morinidazole.ResultsOne-compartment model was conducted to establish the morinidazole PPK model. Disease condition was the significant covariate for CL and weight was the significant covariate for V. The AUC0-∞ was 120.44±37.05 (79.25-207.20) μg×h/mL in hepatic impairment group and was 79.46±23.71 (42.94-116.75) μg×h/mL in control group. The AUC0-∞ was 164.9±44.8 μg×h/mL and 77.2±23.1 μg×h/mLin in the 3 subjects with both hepatic impairment and mild renal impairment and in the 3 matched healthy subjects, respectively.ConclusionIt is not necessary to adjust morinidazole dosage for patients with moderate hepatic impairment without confirmed renal dysfunction. For patient with moderate hepatic and mild renal impairment, morinidazole regimen should be considered as 500mg every 24 hours. When used in patients with moderate/severe hepatic impairment combined with renal dysfunction, both dosage and interval adjustment of morinidazole should be considered.

scholarly journals Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment

2005 ◽  
Vol 60 (5) ◽  
pp. 469-476 ◽  
Author(s):  
Gregory Holmes ◽  
Lawrence Galitz ◽  
Peter Hu ◽  
William Lyness
Keyword(s):  
Renal Impairment ◽  
Insulin Aspart ◽  
Hepatic Impairment

Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment

2014 ◽  
Vol 108 (5) ◽  
pp. 891-901 ◽  
Author(s):  
Prasarn Manitpisitkul ◽  
Christopher R. Curtin ◽  
Kevin Shalayda ◽  
Shean-Sheng Wang ◽  
Lisa Ford ◽  
...  
Keyword(s):  
Renal Impairment ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hepatic Impairment ◽  
Stage Renal Disease ◽  
End Stage

Posology adjustments of oral antineoplastic agents for special populations: patients with renal impairment, hepatic impairment and hematologic toxicities

2018 ◽  
Vol 17 (6) ◽  
pp. 553-572 ◽  
Author(s):  
Julieta González ◽  
Matías Quiroga ◽  
Vicente Escudero-Vilaplana ◽  
Roberto Collado-Borrell ◽  
Ana Herranz-Alonso ◽  
...  
Keyword(s):  
Renal Impairment ◽  
Hepatic Impairment ◽  
Antineoplastic Agents ◽  
Special Populations
Sign in / Sign up

Export Citation Format

Share Document